`8K 1 c82013_8k.htm
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`Date of report (Date of earliest event reported): July 20, 2015
`
`
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`Washington, DC 20549
`
`FORM 8K
`
`CURRENT REPORT Pursuant
`to Section 13 or 15(d) of the
`Securities Exchange Act of 1934
`
`
`Enzo Biochem, Inc.
`(Exact Name of Registrant as Specified in Its Charter)
`
`New York
`(State or Other Jurisdiction of Incorporation)
`
`
`00109974
`(Commission File Number)
`
`527 Madison Avenue
`New York, New York
`(Address of Principal Executive Offices)
`
`132866202
`(IRS Employer Identification No.)
`
`
`10022
`(Zip Code)
`
`
`(212) 5830100
`(Registrant’s Telephone Number, Including Area Code)
`
`(Former Name or Former Address, if Changed Since Last Report)
`
`Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant
`under any of the following provisions ( see General Instruction A.2. below):
`
` Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
`
`
` Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
`
`
` Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
`
`
` Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`1/3
`
`Enzo Exhibit 2127
`BD v. Enzo
`Case IPR2017-00181
`
`Exhibit 2127 Page 1
`
`
`
`1/10/2017
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`Item 8.01 Other events
`On July 20, 2015, Enzo Life Sciences, Inc., a wholly owned subsidiary of Enzo Biochem, Inc. (“Enzo Life Sciences”),
`executed a settlement with Siemens Healthcare Diagnostics Inc. (“Siemens”), providing for an upfront payment of $9.5 million (plus
`potential licensing royalties up to $5.0 million depending on additional sales of Siemens product over a five year period) to Enzo
`Life Sciences in an infringement action brought by Enzo Life Sciences regarding its U.S. Patent 7,064,197.
`
`
`This settlement resolves the disputes between Enzo Life Sciences and Siemens and impacts only one of 12 cases originally
`brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various
`companies. This settlement marks the second settlement of these cases, the first of which occurred on July 6, 2015 wherein Luminex
`agreed to pay Enzo $7.1 million. Eleven of the cases remain in active litigation.
`
`Item 9.01. Financial Statements and Exhibits.
`
`(d) Exhibits.
`
`Press Release of Enzo Biochem, Inc., dated July 22, 2015
`99.1
`99.2* Settlement and License Agreement between Enzo Biochem, Inc. and Siemens Healthcare Diagnostics Inc.
`
`*Confidential treatment has been requested or granted for certain portions omitted from this Exhibit pursuant to rule 24b2 under the
`Securities Exchange Act of 1934, as amended.
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`2/3
`
`Exhibit 2127 Page 2
`
`
`
`1/10/2017
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`SIGNATURES
`
`Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
`to be signed on its behalf by the undersigned hereunto duly authorized.
`
`
`
`
`Date: July 22, 2015
`
`
`
`ENZO BIOCHEM, INC.
`
`
`By:
`/s/ Barry W. Weiner
`
`Barry W. Weiner
`
`President
`
`
`
`
`
`
`
`
`https://www.sec.gov/Archives/edgar/data/316253/000093041315003120/c82013_8k.htm
`
`3/3
`
`Exhibit 2127 Page 3
`
`